21:43 , Jul 28, 2017 |  BioCentury  |  Emerging Company Profile

Microbiotal reverse-engineering

Finch Therapeutics Inc. is developing an oral alternative to fecal microbial transplant that it believes entails less biology risk than more advanced oral candidates, with more targeted delivery than full microbiome transplants delivered via enema....
19:55 , Apr 26, 2017 |  BC Extra  |  Financial News

Gates Foundation leads Arsanis' $45.5M series D

Infectious disease company Arsanis Inc. (Waltham, Mass.) raised $45.5 million in a series D round led by the Bill & Melinda Gates Foundation (Seattle. Wash.), a new investor. Also participating were new investors GV and...